Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [99mTc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I/II Clinical Study

Résumé fourni par la source

High Resolution Image Download MS PowerPoint Slide Radionuclide imaging of prostate-specific membrane antigen (PSMA) expression can be used for staging prostate cancer. The pseudo-peptide [ 99m Tc]Tc-BQ0413 demonstrated high affinity and specificity to PSMA in preclinical evaluation. The purpose of this study was to clinically evaluate the safety and tolerability of a single administration of [ 99m Tc]Tc-BQ0413 as well as study its biodistribution using SPECT to estimate dosimetry. [ 99m Tc]Tc-BQ0413 was studied in a single-center diagnostic Phase I open-label exploratory study. Whole-body planar scintigraphy and SPECT/CT imaging were performed 2, 4, and 6 h after administration of 50, 100, or 150 μg (680 ± 140 MBq) of [ 99m Tc]Tc-BQ0413 in five PCa patients per injected mass (NCT05839990). All injections of [ 99m Tc]Tc-BQ0413 were well tolerated. The elimination of [ 99m Tc]Tc-BQ0413 was predominantly renal. The stable physiological uptake of [ 99m Tc]Tc-BQ0413 was observed in the lacrimal and salivary glands, liver, spleen, and kidneys for all tested peptide-injected masses. The average effective doses were 0.007 ± 0.001, 0.0049 ± 0.0003, and 0.0062 ± 0.0008 mSv/MBq for 50, 100, and 150 μg/injection, respectively. The radionuclide-associated dose burden per patient was 4–7 mSv/study for the given activity. Uptake of [ 99m Tc]Tc-BQ0413 in primary tumors was identified in all patients and increased with the peptide-injected mass. Uptake in lymph nodes and bone metastases was the highest at 100 μg/injected mass. The highest tumor lesion/background ratios were observed 6 h after the administration of 100 μg of [ 99m Tc]Tc-BQ0413. The results of the Phase I study showed that injections of [ 99m Tc]Tc-BQ0413 were well tolerated, safe, and associated with low absorbed doses. Imaging using [ 99m Tc]Tc-BQ0413 enabled the visualization of primary prostate cancer lesions as well as metastases in lymph nodes and bones.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.